


Trial title: Efficacy and tolerability of tasipimidine after 3 repeated bed-time doses with a 4-week extension part in patients with insomnia disorder

Abstract	• Main purpose of the trial was to study if tasipimidine can be used in treatment of sleeplessness. • Trial treatments were tasipimidine and placebo. • The trial was divided into two parts. In Part 1, trial treatment was used for 3 days, and in Part 2, for 4 weeks. • Total number of participants was 189 with 74 participants across 3 countries in Part 1 and 115 participants across 4 countries in Part 2. • Topline results: Sleep parameters studied improved during the trial but did not differ from placebo. • Safety: Tasipimidine was safe and well tolerated.
About this summary	This summary shows the main results from a clinical trial. Researchers perform many studies to understand which medicines work and how they work. It takes many people in many countries around the world to advance medical science. Thank you everyone who took part in this trial and the staff who made it possible.
1. Why was this trial done?	This trial investigated a new treatment for sleeplessness. Tasipimidine is a new medicine for humans that is taken as oral solution. The purpose of this trial was to find out if tasipimidine helps in the treatment of sleeplessness and how safe it is in use in humans.
2. What did the researchers want to find out?	Main objective of the trial was to study if tasipimidine has a positive effect in the treatment of sleeplessness.
3. What kind of a trial was this?	This trial was: • a double-blind, meaning that neither the participant nor the trial doctor knew whether the participant got tasipimidine or placebo. Participants were placed on tasipimidine or placebo groups by chance ('randomisation'). • a dose-escalation in Part 1 (the first tasipimidine dose was lower, the next doses were increased), and parallel in Part 2 (groups were receiving different tasipimidine doses or placebo at the same time) • multi-site (trial was conducted at various sites). This trial started in July 2023 and ended in September 2025. There were 2 parts in this trial. In Part 1, the participants were given tasipimidine or placebo oral solution 3 days in the evenings before bedtime in a sleep laboratory. In Part 2, the participants were given tasipimidine or placebo 3 days in the evenings in the sleep laboratory

	as in Part 1 and then they continued taking it at home every evening for up to 4 weeks. Studied sleep parameters were calculated from recordings measured by polysomnography (an equipment which measures brain waves, oxygen level in blood, heart rate and breathing) during the night.																								
4. Who took part in this trial?	In this trial, 64 men and 125 women with insomnia disorder took part. They were from Finland (18 participants), Germany (136 participants), Poland (17 participants), and the United States (18 participants). There were 74 participants in Part 1 and 115 participants in Part 2. Men and women who were 18-65 years or older and had insomnia disorder were able to take part in this trial.																								
5. Which medicines were studied in this trial?	The trial medicines were tasipimidine and placebo oral solution. In Part 1, a total of 4 dose levels of tasipimidine were studied. In Part 2, 3 dose levels used in Part 1 were further studied. Dose levels were selected to target the required maximum amount of tasipimidine in blood. Actual dose of tasipimidine was calculated individually for each participant. In Part 1, the participants took trial medication for 3 days, and in Part 2, for 4 weeks. Hereafter, tasipimidine dose levels are presented with TAS A, TAS B, TAS C and TAS D and placebo with PCO.																								
6. What were the overall results of the clinical trial?	• Tasipimidine was safe and well tolerated in all treatment groups. • The overall trial results do not indicate that tasipimidine is efficient in treatment of sleeplessness in the dose levels studied. • One of the studied sleep parameters, the mean time being awake after initially fallen asleep (WASO), decreased in all treatment groups, including placebo. The following figure shows the time curve of mean time in minutes being awake after initially fallen asleep. Time curve of the mean time in minutes being awake after initially fallen asleep at baseline (before trial treatment was taken), after Day 1-2 and after Day 27-28 (4 weeks) in all treatment groups and placebo group <table border="1"><caption>Approximate data from the WASO time curve graph</caption><thead><tr><th>Treatment</th><th>Baseline</th><th>Average Day 1 to 2 Window</th><th>Average Day 27 to 28 Window</th></tr></thead><tbody><tr><td>PEO</td><td>~95</td><td>~85</td><td>~70</td></tr><tr><td>TAS A</td><td>~120</td><td>~85</td><td>~75</td></tr><tr><td>TAS B</td><td>~100</td><td>~80</td><td>~65</td></tr><tr><td>TAS C</td><td>~105</td><td>~85</td><td>~70</td></tr><tr><td>TAS D</td><td>~100</td><td>~85</td><td>~70</td></tr></tbody></table>	Treatment	Baseline	Average Day 1 to 2 Window	Average Day 27 to 28 Window	PEO	~95	~85	~70	TAS A	~120	~85	~75	TAS B	~100	~80	~65	TAS C	~105	~85	~70	TAS D	~100	~85	~70
Treatment	Baseline	Average Day 1 to 2 Window	Average Day 27 to 28 Window																						
PEO	~95	~85	~70																						
TAS A	~120	~85	~75																						
TAS B	~100	~80	~65																						
TAS C	~105	~85	~70																						
TAS D	~100	~85	~70																						

- Another sleep parameter, mean time to fall asleep (LPS), decreased in all treatment groups, including placebo. The following figure shows time curve of mean time to fall asleep.

Time curve of the mean time to fall asleep in minutes at baseline (before trial treatment was taken), after Day 1-2 and after Day 27-28 (4 weeks) in all treatment groups and placebo group



This summary contains only the main results of the trial. Links to the complete list of outcomes based on all endpoints are available in Section 10.

7. What were the side effects?

Side effects are unwanted medical events that the trial doctor thought may be related to the medicine used in the trial. Not everyone in this trial had side effects.

Serious side effects either lead to death, are life-threatening, put a person in the hospital or keep them in the hospital for a longer time. Serious side effects may also cause birth defects or cause a long-lasting disability.

What were the serious side effects in this trial?

None of the participants had serious side effects.

What were the most common side effects?

In the following table, the most common side effects which appeared at least in 4% of participants in any treatment group are presented.

The number of participants who had possible side effects

Participants:	Placebo 48	TAS A 13	TAS B 42	TAS C 35	TAS D 51
Decrease in blood pressure when rising up from lying down (orthostatic hypotension)	6 (13%)	2 (15%)	5 (12%)	3 (9%)	7 (14%)
Headache	2 (4%)	-	2 (5%)	1 (3%)	2 (4%)
Dry mouth	3 (6%)	-	2 (5%)	-	2 (4%)

	Dizziness - - 1 (2%) 2 (6%) 2 (4%) Dizziness postural 2 (4%) - 1 (2%) - 1 (2%) Fast heartbeat 3 (6%) - - - - Nasal dryness 2 (4%) - - - - Stomach pain - 1 (8%) - - -
8. How has this clinical trial helped the participants and researchers?	Trial treatment was only tested in adult men and women participants with insomnia disorder for 3 days in Part 1 and 4 weeks in Part 2. In this trial, researchers got information about effect of tasipimidine for several sleep parameters. According to these results the studied doses of tasipimidine did not have sufficiently good effect on sleeplessness. Researchers also found out that tasipimidine doses studied were tolerated well. Researchers also got more information about the most common side effects. Researcher also found out how the amount of tasipimidine changed in blood by time and if the participant's genes affected the trial results. These results are for this trial only. This trial does not tell if tasipimidine can or cannot be used to treat insomnia disorder. Other trials may find out something different.
9. Are there plans for further studies?	There are currently no plans for further trials.
10. Additional information about the clinical trial	Trial name: Efficacy and tolerability of tasipimidine after 3 repeated bed-time doses with a 4-week extension part in patients with insomnia disorder Short title: UNITAS EU trial number: 2022-502483-21-00 Other identifiers: • More information about this trial, including a detailed scientific summary of trial results, is available at https://euclinicaltrials.eu. Please use protocol identifier 3110012. • Some information about the trial is also available in website www.clinicaltrials.gov. Please use identifier NCT06956495. • Also, some information about the trial is available in web page https://www.isrctn.com/. Please use identifier ISRCTN35042256. The purpose of this summary is to inform the public about results of one clinical trial. This kind of transparency is very important to Orion. The information in this document should not be used for any other purposes.

11. Who sponsored this clinical trial?	This clinical trial was sponsored by: Orion Corporation Orionintie 1 FI-02200 Espoo, FINLAND Phone: +358 10 4261 Email: clinicaltrials@orionpharma.com Website: https://www.orionpharma.com/about-orion/
---	---